TrialAnnals of the rheumatic diseases2020

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.

Jing He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.